Glaukos Reports Q1 2026 Earnings with Strong Sales Growth and Updated Guidance
Glaukos (GKOS) reported Q1 2026 earnings with consolidated net sales of $150.6 million, up 41% year-over-year. The company raised its full-year net sales guidance to $620 million to $635 million and highlighted strong performance in its U.S. glaucoma franchise and international sales.
Tickers: $GKOS
Topics: earnings guidance update market expansion product launch reimbursement sales growth